1st line Relapsed or Metastatic mucosal, HNSCC, not NPC

Treatment

PDL1(+)

Injectible Lesions

PDL1(-)

HPV(+) Only

**ENT0097**
A Phase II Study of Ipilimumab in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

PI: Colevas
Sponsor: National Cancer Institute (NCI)

**ENT0088**
Phase II Macrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma

PI: Colevas
Sponsor: Gilead Sciences, Inc.

**ENT0107**
Randomized Phase II Open-Label Multi-Arm Study of Tislelizumab in Combo w/ Investigational Agents as First-Line Treatment in Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma

PI: Khan
Sponsor: BeiGene, Ltd

**ENT0064**
Phase II: AdPVP-FAAAMP + Co-Admin of Fludarabine Phosphate in Recurrent Local Head & Neck Cancer

PI: Colevas
Sponsor: PNP Therapeutics

**ENT0088**
Phase II Macrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma

PI: Colevas
Sponsor: Gilead Sciences, Inc.